A reason why the ERBB2 gene is amplified and not mutated in breast cancer.
Auteurs
Birnbaum D, Sircoulomb F
Résumé
Alterations of receptor-type tyrosine kinases (RTK) are frequent in human cancers. They can result from translocation, mutation or amplification. The ERBB2 RTK is encoded by a gene that is amplified in about 20% breast cancers. The question is: why is this RTK specifically subjected to this type of alteration? We propose that ERBB2 gene amplification is used to overcome repression of its expression by sequence-specific transcription factors.
Lire l‘article